Stammdaten
Alnylam Pharmaceuticals ist ein biopharmazeutisches Unternehmen im kommerziellen Stadium, das sich auf die Entwicklung von RNAi-Therapeutika konzentriert. Das Unternehmen hat sechs zugelassene Medikamente auf dem Markt, darunter AMVUTTRA® für die Behandlung der hereditären transthyretin-vermittelten Amyloidose (hATTR) mit Polyneuropathie und Kardiomyopathie, ONPATTRO® für hATTR-Amyloidose mit Polyneuropathie, GIVLAARI® für akute hepatische Porphyrie, OXLUMO® für primäre Hyperoxalurie Typ 1 sowie Leqvio® und Qfitlia® in Zusammenarbeit mit Novartis bzw. Sanofi. Alnylam verfügt über mehr als 20 klinische Programme in verschiedenen Entwicklungsphasen und konzentriert sich auf seltene und häufige Krankheiten. Das Unternehmen nutzt verschiedene Liefertechnologien wie GalNAc-Konjugate, Lipid-Nanopartikel (LNP) und C16-Konjugate für die Abgabe an das zentrale Nervensystem und das Auge. Alnylam strebt an, bis Ende 2030 eine führende Position im TTR-Markt zu erreichen, durch nachhaltige Innovation neue Therapien zu liefern und ein nachhaltiges, profitables Wachstum zu erzielen. KI
Unternehmen & Branche
| Name | ALNYLAM PHARMACEUTICALS, INC. |
|---|---|
| Ticker | ALNY |
| CIK | 0001178670 |
| Börse | Nasdaq |
| Sektor | Gesundheit |
| Industrie | Pharmazeutische Erzeugnisse |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 02043Q107 |
|---|---|
| ISIN | US02043Q1076 |
| Typ | Common Stock |
| Marktkapitalisierung | 35,98 Mrd. USD |
| KGV (P/E) | 116,64 |
| Beta | 0,27 |
Sitz & Kontakt
| Geschäftsadresse | 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, 02142 CAMBRIDGE, MA |
|---|---|
| Telefon | (617) 551-8200 |
| EIN (IRS) | 77-0602661 |
Listing & Historie
| Listing-Börsen | Nasdaq |
|---|---|
| Fiskaljahr-Ende | 31.12. |
| SEC-Filer-Status | Large accelerated filer |
| Frühere Namen | ALNYLAM PHARMACEUTICALS INC (bis 2004) |
Bewertung
| KBV (P/B) | 45,59 vs. 34,65 (2021) ▲ |
|---|---|
| KUV (P/S) | 9,69 vs. 24,14 (2021) ▼ |
| EV/EBITDA | 62,1 |
| FCF-Rendite | 1,3 % vs. -3,5 % (2021) ▲ |
Qualität & Bilanz
| Bruttomarge | 81,8 % vs. 86,4 % (2021) ▼ |
|---|---|
| Operative Marge | 13,5 % vs. -83,9 % (2021) ▲ |
| Nettomarge | 8,4 % vs. -101,0 % (2021) ▲ |
| ROIC | 29,6 % vs. -93,7 % (2021) ▲ |
| Nettoverschuldung/EBITDA | -2,5 |
| Zinsdeckungsgrad | 2,0 vs. -5,0 (2021) ▲ |
| Forderungslaufzeit (DSO) | 76 T vs. 86 T (2021) ▼ |
| Lagerreichweite (DIO) | 45 T vs. 274 T (2021) ▼ |
| Verbindlichkeitslaufzeit (DPO) | 62 T vs. 233 T (2021) ▼ |
| Cash-Conversion-Cycle (CCC) | 59 T vs. 127 T (2021) ▼ |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | Verlauf |
|---|---|---|---|---|---|---|
| Bewertung | ||||||
| KBV (P/B) | 34,65 | – | – | 453,50 | 66,70 | |
| KUV (P/S) | 24,14 | 28,39 | 13,17 | 13,53 | 14,17 | |
| FCF-Rendite | -3,5 % | -2,1 % | 0,2 % | -0,1 % | 0,9 % | |
| Qualität & Bilanz | ||||||
| Bruttomarge | 86,4 % | 86,5 % | 85,3 % | 86,4 % | 81,8 % | |
| Operative Marge | -83,9 % | -75,7 % | -15,4 % | -7,9 % | 13,5 % | |
| Nettomarge | -101,0 % | -109,0 % | -24,1 % | -12,4 % | 8,4 % | |
| ROIC | -93,7 % | -779,7 % | -688,2 % | -82,2 % | 29,6 % | |
| Zinsdeckungsgrad | -5,0 | -5,0 | -2,3 | -1,2 | 2,0 | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Glück Conviction Score™ ⓘ
ⓘ
ALNY
ALNYLAM PHARMACEUTICALS, INC.
ⓘ
Eingeschränkte Aussagekraft — erst 61 % der Signal-Gewichte sind mit Daten unterlegt.
Effektiv
Neutral
Handelsvolumen
Hoch
Insider
0,0
Keine Insider-Käufe
Institutionell
45,5
109 neu, 333 erhöht, -11906389K $ netto
Aktivist
20,0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,71% (Stand: 30.06.2026)
Score-Verlauf (90 Tage)
Konviktions-Verlauf — oben stark · Mitte neutral · unten schwach
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (24 Monate)
Indexierte Darstellung (Start = 100) — die Kursform bleibt sichtbar, absolute Kurse sind angemeldeten Mitgliedern vorbehalten.
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bärisch | 10 % | 291.63 | -4.5 % vs SMA50 | |
| Kurs vs SMA200 | Bärisch | 15 % | 353.53 | -21.3 % vs SMA200 | |
| EMA20 vs EMA50 | Bärisch | 5 % | 283.49 | EMA50: 292.28 | |
| MACD-Histogramm | Bärisch | 10 % | -1.992 | Bearisch | |
| RSI(14) | Neutral | 10 % | 44.6 | Neutral (30–70) | |
| Stoch %K(14) | Bullisch | 5 % | 13.7 | Überverkauft | |
| ADX(14)+DI | Neutral | 10 % | 22.6 | +DI: 30.7 / −DI: 19.3 | |
| Z-Score(60) | Neutral | 5 % | -1.15 | In Range | |
| 52W-Position | Bärisch | 5 % | 5.1 % | Hoch 491.22 / Tief 266.99 | |
| Bollinger(20,2σ) | Neutral | 5 % | 33.8 % | Upper 327.48 / Mid 290.38 / Lower 253.29 | |
| LinReg-Slope(60) | Neutral | 10 % | -0.2457 | R²=0.12 / annualisiert -21.2 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-06-01 | PYOTT DAVID E I | Director | Open Market Sale | -1.222 | 299,87 | -366.441,14 | -173,6% | |
| 2026-06-01 | PYOTT DAVID E I | Director | Open Market Sale | -17 | 302,65 | -5.145,05 | -2,4% | |
| 2026-06-01 | PYOTT DAVID E I | Director | Open Market Sale | -1.175 | 298,91 | -351.219,25 | -166,4% | |
| 2026-06-01 | PYOTT DAVID E I | Director | Open Market Sale | -921 | 297,71 | -274.190,91 | -129,9% | |
| 2026-06-01 | PYOTT DAVID E I | Director | Open Market Sale | -495 | 300,72 | -148.856,40 | -70,5% | |
| 2026-04-06 | McLaughlin Melissa | Officer, Chief Human Resources Officer | Open Market Sale | -56 | 320,14 | -17.927,84 | -8,5% | |
| 2026-04-06 | McLaughlin Melissa | Officer, Chief Human Resources Officer | Open Market Sale | -909 | 329,76 | -299.751,84 | -142,0% | |
| 2026-04-06 | McLaughlin Melissa | Officer, Chief Human Resources Officer | Open Market Sale | -829 | 330,46 | -273.951,34 | -129,8% | |
| 2026-04-06 | McLaughlin Melissa | Officer, Chief Human Resources Officer | Open Market Sale | -293 | 331,89 | -97.243,77 | -46,1% | |
| 2026-04-06 | McLaughlin Melissa | Officer, Chief Human Resources Officer | Open Market Sale | -199 | 333,94 | -66.454,06 | -31,5% | |
| 2026-04-02 | McLaughlin Melissa | Officer, Chief Human Resources Officer | Open Market Sale | -8 | 325,49 | -2.603,92 | -1,2% | |
| 2026-04-02 | McLaughlin Melissa | Officer, Chief Human Resources Officer | Open Market Sale | -245 | 322,86 | -79.100,70 | -37,5% | |
| 2026-04-02 | McLaughlin Melissa | Officer, Chief Human Resources Officer | Open Market Sale | -224 | 321,64 | -72.047,36 | -34,1% | |
| 2026-04-02 | McLaughlin Melissa | Officer, Chief Human Resources Officer | Open Market Sale | -265 | 316,61 | -83.901,65 | -39,8% | |
| 2026-04-02 | McLaughlin Melissa | Officer, Chief Human Resources Officer | Open Market Sale | -359 | 317,44 | -113.960,96 | -54,0% | |
| 2026-04-02 | McLaughlin Melissa | Officer, Chief Human Resources Officer | Open Market Sale | -86 | 319,69 | -27.493,34 | -13,0% | |
| 2026-04-02 | McLaughlin Melissa | Officer, Chief Human Resources Officer | Open Market Sale | -147 | 320,62 | -47.131,14 | -22,3% | |
| 2026-04-02 | McLaughlin Melissa | Officer, Chief Human Resources Officer | Open Market Sale | -209 | 318,47 | -66.560,23 | -31,5% | |
| 2026-04-02 | McLaughlin Melissa | Officer, Chief Human Resources Officer | Open Market Sale | -81 | 323,64 | -26.214,84 | -12,4% | |
| 2026-03-05 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -124 | 321,81 | -39.904,44 | -18,9% | |
| 2026-03-05 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -153 | 326,24 | -49.914,72 | -23,7% | |
| 2026-03-05 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -500 | 326,08 | -163.040,00 | -77,3% | |
| 2026-03-05 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -654 | 322,33 | -210.803,82 | -99,9% | |
| 2026-03-05 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -510 | 324,59 | -165.540,90 | -78,4% | |
| 2026-03-05 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -148 | 324,60 | -48.040,80 | -22,8% | |
| 2026-03-05 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -233 | 323,25 | -75.317,25 | -35,7% | |
| 2026-03-05 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -740 | 323,55 | -239.427,00 | -113,4% | |
| 2026-03-04 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -289 | 321,82 | -93.005,98 | -44,1% | |
| 2026-03-04 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -272 | 324,88 | -88.367,36 | -41,9% | |
| 2026-03-04 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -102 | 320,01 | -32.641,02 | -15,5% | |
| 2026-03-04 | Greenstreet Yvonne | Director, Officer, Chief Executive Officer | Open Market Sale | -135 | 319,03 | -43.069,05 | -20,4% | |
| 2026-03-04 | Poulton Jeffrey V. | Officer, EVP, Chief Financial Officer | Open Market Sale | -374 | 323,01 | -120.805,74 | -57,2% | |
| 2026-03-04 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -215 | 320,81 | -68.974,15 | -32,7% | |
| 2026-03-04 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -106 | 319,03 | -33.817,18 | -16,0% | |
| 2026-03-04 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -350 | 323,01 | -113.053,50 | -53,6% | |
| 2026-03-04 | Greenstreet Yvonne | Director, Officer, Chief Executive Officer | Open Market Sale | -345 | 324,88 | -112.083,60 | -53,1% | |
| 2026-03-04 | Greenstreet Yvonne | Director, Officer, Chief Executive Officer | Open Market Sale | -129 | 320,01 | -41.281,29 | -19,6% | |
| 2026-03-04 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -215 | 320,81 | -68.974,15 | -32,7% | |
| 2026-03-04 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -57 | 325,67 | -18.563,19 | -8,8% | |
| 2026-03-04 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -289 | 321,82 | -93.005,98 | -44,1% | |
| 2026-03-04 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -767 | 323,84 | -248.385,28 | -117,7% | |
| 2026-03-04 | Greenstreet Yvonne | Director, Officer, Chief Executive Officer | Open Market Sale | -265 | 325,67 | -86.302,55 | -40,9% | |
| 2026-03-04 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -208 | 325,67 | -67.739,36 | -32,1% | |
| 2026-03-04 | Greenstreet Yvonne | Director, Officer, Chief Executive Officer | Open Market Sale | -274 | 320,81 | -87.901,94 | -41,7% | |
| 2026-03-04 | Greenstreet Yvonne | Director, Officer, Chief Executive Officer | Open Market Sale | -368 | 321,82 | -118.429,76 | -56,1% | |
| 2026-03-04 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -29 | 319,03 | -9.251,87 | -4,4% | |
| 2026-03-04 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -350 | 323,01 | -113.053,50 | -53,6% | |
| 2026-03-04 | Poulton Jeffrey V. | Officer, EVP, Chief Financial Officer | Open Market Sale | -291 | 324,88 | -94.540,08 | -44,8% | |
| 2026-03-04 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -106 | 319,03 | -33.817,18 | -16,0% | |
| 2026-03-04 | Greenstreet Yvonne | Director, Officer, Chief Executive Officer | Open Market Sale | -444 | 323,01 | -143.416,44 | -68,0% | |
| 2026-03-04 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -208 | 325,67 | -67.739,36 | -32,1% | |
| 2026-03-04 | Poulton Jeffrey V. | Officer, EVP, Chief Financial Officer | Open Market Sale | -818 | 323,84 | -264.901,12 | -125,5% | |
| 2026-03-04 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -272 | 324,88 | -88.367,36 | -41,9% | |
| 2026-03-04 | Poulton Jeffrey V. | Officer, EVP, Chief Financial Officer | Open Market Sale | -223 | 325,67 | -72.624,41 | -34,4% | |
| 2026-03-04 | Poulton Jeffrey V. | Officer, EVP, Chief Financial Officer | Open Market Sale | -114 | 319,03 | -36.369,42 | -17,2% | |
| 2026-03-04 | Poulton Jeffrey V. | Officer, EVP, Chief Financial Officer | Open Market Sale | -109 | 320,01 | -34.881,09 | -16,5% | |
| 2026-03-04 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -96 | 323,01 | -31.008,96 | -14,7% | |
| 2026-03-04 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -767 | 323,84 | -248.385,28 | -117,7% | |
| 2026-03-04 | Poulton Jeffrey V. | Officer, EVP, Chief Financial Officer | Open Market Sale | -309 | 321,82 | -99.442,38 | -47,1% | |
| 2026-03-04 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -28 | 320,01 | -8.960,28 | -4,2% | |
| 2026-03-04 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -102 | 320,01 | -32.641,02 | -15,5% | |
| 2026-03-04 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -210 | 323,84 | -68.006,40 | -32,2% | |
| 2026-03-04 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -75 | 324,88 | -24.366,00 | -11,5% | |
| 2026-03-04 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -79 | 321,82 | -25.423,78 | -12,0% | |
| 2026-03-04 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -59 | 320,81 | -18.927,79 | -9,0% | |
| 2026-03-04 | Poulton Jeffrey V. | Officer, EVP, Chief Financial Officer | Open Market Sale | -230 | 320,81 | -73.786,30 | -35,0% | |
| 2026-03-04 | Greenstreet Yvonne | Director, Officer, Chief Executive Officer | Open Market Sale | -973 | 323,84 | -315.096,32 | -149,3% | |
| 2026-03-03 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -355 | 316,74 | -112.442,70 | -53,3% | |
| 2026-03-03 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -463 | 321,50 | -148.854,50 | -70,5% | |
| 2026-03-03 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -317 | 319,06 | -101.142,02 | -47,9% | |
| 2026-03-03 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -640 | 320,48 | -205.107,20 | -97,2% | |
| 2026-03-03 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -282 | 318,62 | -89.850,84 | -42,6% | |
| 2026-03-03 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -289 | 316,55 | -91.482,95 | -43,3% | |
| 2026-03-03 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -359 | 321,58 | -115.447,22 | -54,7% | |
| 2026-03-03 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -722 | 320,51 | -231.408,22 | -109,6% | |
| 2026-03-02 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -81 | 330,85 | -26.798,85 | -12,7% | |
| 2026-03-02 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -90 | 324,65 | -29.218,50 | -13,8% | |
| 2026-03-02 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -37 | 332,64 | -12.307,68 | -5,8% | |
| 2026-03-02 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -392 | 326,81 | -128.109,52 | -60,7% | |
| 2026-03-02 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -94 | 331,93 | -31.201,42 | -14,8% | |
| 2026-03-02 | Poulton Jeffrey V. | Officer, EVP, Chief Financial Officer | Open Market Sale | -541 | 326,81 | -176.804,21 | -83,8% | |
| 2026-03-02 | Poulton Jeffrey V. | Officer, EVP, Chief Financial Officer | Open Market Sale | -129 | 331,93 | -42.818,97 | -20,3% | |
| 2026-03-02 | Poulton Jeffrey V. | Officer, EVP, Chief Financial Officer | Open Market Sale | -138 | 328,71 | -45.361,98 | -21,5% | |
| 2026-03-02 | Poulton Jeffrey V. | Officer, EVP, Chief Financial Officer | Open Market Sale | -112 | 330,85 | -37.055,20 | -17,6% | |
| 2026-03-02 | Poulton Jeffrey V. | Officer, EVP, Chief Financial Officer | Open Market Sale | -53 | 332,64 | -17.629,92 | -8,4% | |
| 2026-03-02 | Poulton Jeffrey V. | Officer, EVP, Chief Financial Officer | Open Market Sale | -234 | 329,71 | -77.152,14 | -36,6% | |
| 2026-03-02 | Poulton Jeffrey V. | Officer, EVP, Chief Financial Officer | Open Market Sale | -65 | 323,62 | -21.035,30 | -10,0% | |
| 2026-03-02 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -100 | 328,71 | -32.871,00 | -15,6% | |
| 2026-03-02 | Greenstreet Yvonne | Director, Officer, Chief Executive Officer | Open Market Sale | -722 | 329,71 | -238.050,62 | -112,8% | |
| 2026-03-02 | Greenstreet Yvonne | Director, Officer, Chief Executive Officer | Open Market Sale | -1.098 | 325,63 | -357.541,74 | -169,4% | |
| 2026-03-02 | Greenstreet Yvonne | Director, Officer, Chief Executive Officer | Open Market Sale | -399 | 331,93 | -132.440,07 | -62,8% | |
| 2026-03-02 | Greenstreet Yvonne | Director, Officer, Chief Executive Officer | Open Market Sale | -200 | 323,62 | -64.724,00 | -30,7% | |
| 2026-03-02 | Greenstreet Yvonne | Director, Officer, Chief Executive Officer | Open Market Sale | -346 | 330,85 | -114.474,10 | -54,2% | |
| 2026-03-02 | Greenstreet Yvonne | Director, Officer, Chief Executive Officer | Open Market Sale | -1.399 | 327,67 | -458.410,33 | -217,2% | |
| 2026-03-02 | Greenstreet Yvonne | Director, Officer, Chief Executive Officer | Open Market Sale | -382 | 324,65 | -124.016,30 | -58,8% | |
| 2026-03-02 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -170 | 329,71 | -56.050,70 | -26,6% | |
| 2026-03-02 | Greenstreet Yvonne | Director, Officer, Chief Executive Officer | Open Market Sale | -160 | 332,64 | -53.222,40 | -25,2% | |
| 2026-03-02 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -277 | 325,63 | -90.199,51 | -42,7% | |
| 2026-03-02 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -421 | 326,81 | -137.587,01 | -65,2% | |
| 2026-03-02 | Greenstreet Yvonne | Director, Officer, Chief Executive Officer | Open Market Sale | -1.669 | 326,81 | -545.445,89 | -258,4% | |
| 2026-03-02 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -353 | 327,67 | -115.667,51 | -54,8% | |
| 2026-03-02 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -101 | 331,93 | -33.524,93 | -15,9% | |
| 2026-03-02 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -107 | 328,71 | -35.171,97 | -16,7% | |
| 2026-03-02 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -47 | 323,62 | -15.210,14 | -7,2% | |
| 2026-03-02 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -258 | 325,63 | -84.012,54 | -39,8% | |
| 2026-03-02 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -182 | 329,71 | -60.007,22 | -28,4% | |
| 2026-03-02 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -37 | 332,64 | -12.307,68 | -5,8% | |
| 2026-03-02 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -42 | 332,64 | -13.970,88 | -6,6% | |
| 2026-03-02 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -50 | 323,62 | -16.181,00 | -7,7% | |
| 2026-03-02 | Greenstreet Yvonne | Director, Officer, Chief Executive Officer | Open Market Sale | -424 | 328,71 | -139.373,04 | -66,0% | |
| 2026-03-02 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -87 | 330,85 | -28.783,95 | -13,6% | |
| 2026-03-02 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -97 | 324,65 | -31.491,05 | -14,9% | |
| 2026-03-02 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -329 | 327,67 | -107.803,43 | -51,1% | |
| 2026-03-02 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -392 | 326,81 | -128.109,52 | -60,7% | |
| 2026-03-02 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -329 | 327,67 | -107.803,43 | -51,1% | |
| 2026-03-02 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -100 | 328,71 | -32.871,00 | -15,6% | |
| 2026-03-02 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -170 | 329,71 | -56.050,70 | -26,6% | |
| 2026-03-02 | Poulton Jeffrey V. | Officer, EVP, Chief Financial Officer | Open Market Sale | -124 | 324,65 | -40.256,60 | -19,1% | |
| 2026-03-02 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -258 | 325,63 | -84.012,54 | -39,8% | |
| 2026-03-02 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -81 | 330,85 | -26.798,85 | -12,7% | |
| 2026-03-02 | Poulton Jeffrey V. | Officer, EVP, Chief Financial Officer | Open Market Sale | -454 | 327,67 | -148.762,18 | -70,5% | |
| 2026-03-02 | Poulton Jeffrey V. | Officer, EVP, Chief Financial Officer | Open Market Sale | -356 | 325,63 | -115.924,28 | -54,9% | |
| 2026-03-02 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -90 | 324,65 | -29.218,50 | -13,8% | |
| 2026-03-02 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -94 | 331,93 | -31.201,42 | -14,8% | |
| 2026-03-02 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -47 | 323,62 | -15.210,14 | -7,2% | |
| 2026-02-27 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -2.259 | 330,73 | -747.119,07 | -354,0% | |
| 2026-02-27 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -1.159 | 331,49 | -384.196,91 | -182,0% | |
| 2026-02-27 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -942 | 332,48 | -313.196,16 | -148,4% | |
| 2026-02-27 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -127 | 328,92 | -41.772,84 | -19,8% | |
| 2026-02-27 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -140 | 334,39 | -46.814,60 | -22,2% | |
| 2026-02-17 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -2.041 | 331,96 | -677.531,58 | -321,0% | |
| 2026-02-13 | Poulton Jeffrey V. | Officer, EVP, Chief Financial Officer | Open Market Sale | -2.242 | 310,08 | -695.201,15 | -329,4% | |
| 2026-02-13 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -1.959 | 310,08 | -607.448,29 | -287,8% | |
| 2026-02-13 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -2.242 | 310,08 | -695.201,15 | -329,4% | |
| 2026-02-13 | Greenstreet Yvonne | Director, Officer, Chief Executive Officer | Open Market Sale | -6.958 | 310,08 | -2.157.542,21 | -1022,3% | |
| 2026-02-13 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -1.959 | 310,08 | -607.448,29 | -287,8% | |
| 2026-01-13 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -485 | 371,24 | -180.051,40 | -85,3% | |
| 2026-01-13 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -562 | 368,76 | -207.243,12 | -98,2% | |
| 2026-01-13 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -644 | 370,00 | -238.280,00 | -112,9% | |
| 2026-01-13 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -122 | 374,33 | -45.668,26 | -21,6% | |
| 2026-01-13 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -197 | 367,52 | -72.401,44 | -34,3% | |
| 2026-01-13 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -280 | 372,93 | -104.420,40 | -49,5% | |
| 2026-01-12 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -199 | 364,83 | -72.601,17 | -34,4% | |
| 2026-01-12 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -220 | 365,56 | -80.423,20 | -38,1% | |
| 2026-01-12 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -41 | 367,40 | -15.063,40 | -7,1% | |
| 2026-01-12 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -42 | 355,16 | -14.916,72 | -7,1% | |
| 2026-01-12 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -123 | 358,18 | -44.056,14 | -20,9% | |
| 2026-01-12 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -41 | 356,09 | -14.599,69 | -6,9% | |
| 2026-01-12 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -2 | 372,46 | -744,92 | -0,4% | |
| 2026-01-12 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -39 | 353,95 | -13.804,05 | -6,5% | |
| 2026-01-12 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -40 | 369,48 | -14.779,20 | -7,0% | |
| 2026-01-12 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -19 | 375,65 | -7.137,35 | -3,4% | |
| 2026-01-12 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -14 | 374,44 | -5.242,16 | -2,5% | |
| 2026-01-12 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -15 | 377,82 | -5.667,30 | -2,7% | |
| 2026-01-12 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -19 | 370,87 | -7.046,53 | -3,3% | |
| 2026-01-12 | Greenstreet Yvonne | Director, Officer, Chief Executive Officer | Open Market Sale | -316 | 366,41 | -115.785,56 | -54,9% | |
| 2026-01-12 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -47 | 363,55 | -17.086,85 | -8,1% | |
| 2026-01-12 | Poulton Jeffrey V. | Officer, EVP, Chief Financial Officer | Open Market Sale | -365 | 364,83 | -133.162,95 | -63,1% | |
| 2026-01-12 | Poulton Jeffrey V. | Officer, EVP, Chief Financial Officer | Open Market Sale | -405 | 365,56 | -148.051,80 | -70,2% | |
| 2026-01-12 | Poulton Jeffrey V. | Officer, EVP, Chief Financial Officer | Open Market Sale | -284 | 360,22 | -102.302,48 | -48,5% | |
| 2026-01-12 | Poulton Jeffrey V. | Officer, EVP, Chief Financial Officer | Open Market Sale | -181 | 361,45 | -65.422,45 | -31,0% | |
| 2026-01-12 | Poulton Jeffrey V. | Officer, EVP, Chief Financial Officer | Open Market Sale | -226 | 358,18 | -80.948,68 | -38,4% | |
| 2026-01-12 | Poulton Jeffrey V. | Officer, EVP, Chief Financial Officer | Open Market Sale | -176 | 357,17 | -62.861,92 | -29,8% | |
| 2026-01-12 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -2 | 372,46 | -744,92 | -0,4% | |
| 2026-01-12 | Poulton Jeffrey V. | Officer, EVP, Chief Financial Officer | Open Market Sale | -135 | 362,38 | -48.921,30 | -23,2% | |
| 2026-01-12 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -14 | 374,44 | -5.242,16 | -2,5% | |
| 2026-01-12 | Greenstreet Yvonne | Director, Officer, Chief Executive Officer | Open Market Sale | -94 | 377,82 | -35.515,08 | -16,8% | |
| 2026-01-12 | Poulton Jeffrey V. | Officer, EVP, Chief Financial Officer | Open Market Sale | -156 | 359,14 | -56.025,84 | -26,5% | |
| 2026-01-12 | Fitzgerald Kevin Joseph | Officer, CSO & EVP, Head of Research | Open Market Sale | -15 | 377,82 | -5.667,30 | -2,7% | |
| 2026-01-12 | Poulton Jeffrey V. | Officer, EVP, Chief Financial Officer | Open Market Sale | -170 | 368,62 | -62.665,40 | -29,7% | |
| 2026-01-12 | Greenstreet Yvonne | Director, Officer, Chief Executive Officer | Open Market Sale | -301 | 363,55 | -109.428,55 | -51,8% | |
| 2026-01-12 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -50 | 366,41 | -18.320,50 | -8,7% | |
| 2026-01-12 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -155 | 360,22 | -55.834,10 | -26,5% | |
| 2026-01-12 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -123 | 358,18 | -44.056,14 | -20,9% | |
| 2026-01-12 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -98 | 361,45 | -35.422,10 | -16,8% | |
| 2026-01-12 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -98 | 361,45 | -35.422,10 | -16,8% | |
| 2026-01-12 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -96 | 357,17 | -34.288,32 | -16,2% | |
| 2026-01-12 | Greenstreet Yvonne | Director, Officer, Chief Executive Officer | Open Market Sale | -464 | 362,38 | -168.144,32 | -79,7% | |
| 2026-01-12 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -85 | 359,14 | -30.526,90 | -14,5% | |
| 2026-01-12 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -50 | 366,41 | -18.320,50 | -8,7% | |
| 2026-01-12 | Poulton Jeffrey V. | Officer, EVP, Chief Financial Officer | Open Market Sale | -76 | 356,09 | -27.062,84 | -12,8% | |
| 2026-01-12 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -47 | 363,55 | -17.086,85 | -8,1% | |
| 2026-01-12 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -42 | 355,16 | -14.916,72 | -7,1% | |
| 2026-01-12 | Tanguler Tolga | Officer, EVP, Chief Commercial Officer | Open Market Sale | -73 | 362,38 | -26.453,74 | -12,5% | |
| 2026-01-12 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -41 | 367,40 | -15.063,40 | -7,1% | |
| 2026-01-12 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -41 | 356,09 | -14.599,69 | -6,9% | |
| 2026-01-12 | Poulton Jeffrey V. | Officer, EVP, Chief Financial Officer | Open Market Sale | -76 | 367,40 | -27.922,40 | -13,2% | |
| 2026-01-12 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -73 | 362,38 | -26.453,74 | -12,5% | |
| 2026-01-12 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -40 | 369,48 | -14.779,20 | -7,0% | |
| 2026-01-12 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -92 | 368,62 | -33.913,04 | -16,1% | |
| 2026-01-12 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -39 | 353,95 | -13.804,05 | -6,5% | |
| 2026-01-12 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -19 | 375,65 | -7.137,35 | -3,4% | |
| 2026-01-12 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -18 | 370,87 | -6.675,66 | -3,2% | |
| 2026-01-12 | Greenstreet Yvonne | Director, Officer, Chief Executive Officer | Open Market Sale | -261 | 367,40 | -95.891,40 | -45,4% | |
| 2026-01-12 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -199 | 364,83 | -72.601,17 | -34,4% | |
| 2026-01-12 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -220 | 365,56 | -80.423,20 | -38,1% | |
| 2026-01-12 | Greenstreet Yvonne | Director, Officer, Chief Executive Officer | Open Market Sale | -21 | 372,46 | -7.821,66 | -3,7% | |
| 2026-01-12 | Greenstreet Yvonne | Director, Officer, Chief Executive Officer | Open Market Sale | -88 | 374,44 | -32.950,72 | -15,6% | |
| 2026-01-12 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -15 | 377,82 | -5.667,30 | -2,7% | |
| 2026-01-12 | Garg Pushkal | Officer, EVP Chief R&D | Open Market Sale | -14 | 374,44 | -5.242,16 | -2,5% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
⚠ Vorläufige Daten: Erst 2951 von typischerweise 8401 Fonds (35 %) haben für das aktuelle 13F-Quartal eingereicht — Werte können sich in den kommenden Wochen noch deutlich ändern.
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| FMR LLC | 33.023.166 | 0 | 33.023.166 | 4.847.444.679 | Neu | +100,0% | |
| Capital World Investors | 10.802.348 | 0 | 10.802.348 | 3.573.758.048 | Neu | +100,0% | |
| BlackRock, Inc. | 27.044.908 | 0 | 27.044.908 | 3.477.179.610 | Neu | +100,0% | |
| Capital Research Global Investors | 9.471.181 | 0 | 9.471.181 | 3.133.497.254 | Neu | +100,0% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.946.706 | 0 | 5.946.706 | 1.967.586.614 | Neu | +100,0% | |
| STATE STREET CORP | 26.092.698 | 0 | 26.092.698 | 1.128.657.059 | Neu | +100,0% | |
| Invesco Ltd. | 2.783.394 | 0 | 2.783.394 | 920.941.573 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 2.660.385 | 0 | 2.660.385 | 884.565.832 | Neu | +100,0% | |
| BAILLIE GIFFORD & CO | 2.493.866 | 0 | 2.493.866 | 825.145.443 | Neu | +100,0% | |
| TWO SIGMA INVESTMENTS, LP | 7.992.577 | 0 | 7.992.577 | 666.972.952 | Neu | +100,0% | |
| WELLINGTON MANAGEMENT GROUP LLP | 1.935.925 | 0 | 1.935.925 | 640.539.505 | Neu | +100,0% | |
| DODGE & COX | 1.929.253 | 0 | 1.929.253 | 638.331.940 | Neu | +100,0% | |
| AMERICAN CENTURY COMPANIES INC | 1.802.363 | 0 | 1.802.363 | 596.349.775 | Neu | +100,0% | |
| D. E. Shaw & Co., Inc. | 1.474.362 | 0 | 1.474.362 | 487.822.155 | Neu | +100,0% | |
| Clearbridge Investments, LLC | 1.356.036 | 0 | 1.356.036 | 448.671.479 | Neu | +100,0% | |
| Orbis Allan Gray Ltd | 1.334.825 | 0 | 1.334.825 | 441.653.547 | Neu | +100,0% | |
| MARSHALL WACE, LLP | 1.099.318 | 0 | 1.099.318 | 363.731.347 | Neu | +100,0% | |
| MORGAN STANLEY | 4.122.681 | 0 | 4.122.681 | 335.756.376 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 11.872.912 | 0 | 11.872.912 | 333.898.281 | Neu | +100,0% | |
| Legal & General Group Plc | 934.881 | 0 | 934.881 | 309.324.079 | Neu | +100,0% | |
| AQR CAPITAL MANAGEMENT LLC | 913.104 | 0 | 913.104 | 297.872.637 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 858.120 | 0 | 858.120 | 283.926.165 | Neu | +100,0% | |
| Qube Research & Technologies Ltd | 838.187 | 0 | 838.187 | 277.330.933 | Neu | +100,0% | |
| ROYAL BANK OF CANADA | 793.515 | 0 | 793.515 | 261.892.000 | Neu | +100,0% | |
| DEUTSCHE BANK AG\ | 771.864 | 0 | 771.864 | 255.386.641 | Neu | +100,0% | |
| Amundi | 5.747.544 | 0 | 5.747.544 | 247.346.292 | Neu | +100,0% | |
| WELLS FARGO & COMPANY/MN | 1.622.763 | 0 | 1.622.763 | 237.002.789 | Neu | +100,0% | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 14.462.365 | 0 | 14.462.365 | 236.917.314 | Neu | +100,0% | |
| FEDERATED HERMES, INC. | 687.816 | 0 | 687.816 | 227.577.681 | Neu | +100,0% | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 677.519 | 0 | 677.519 | 224.170.712 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 673.356 | 0 | 673.356 | 222.793.300 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 596.768 | 0 | 596.768 | 197.452.628 | Neu | +100,0% | |
| LOOMIS SAYLES & CO L P | 516.957 | 0 | 516.957 | 171.045.659 | Neu | +100,0% | |
| Squarepoint Ops LLC | 508.223 | 0 | 508.223 | 168.155.744 | Neu | +100,0% | |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 496.004 | 0 | 496.004 | 164.108.974 | Neu | +100,0% | |
| MILLENNIUM MANAGEMENT LLC | 493.087 | 0 | 493.087 | 163.147.696 | Neu | +100,0% | |
| FRANKLIN RESOURCES INC | 2.705.390 | 0 | 2.705.390 | 158.507.680 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 843.388 | 0 | 843.388 | 155.785.748 | Neu | +100,0% | |
| UBS Group AG | 484.528 | 0 | 484.528 | 152.844.009 | Neu | +100,0% | |
| BNP PARIBAS FINANCIAL MARKETS | 32.598.965 | 0 | 32.598.965 | 134.378.407 | Neu | +100,0% | |
| RAYMOND JAMES FINANCIAL INC | 406.956 | 0 | 406.956 | 129.968.886 | Neu | +100,0% | |
| Swiss National Bank | 387.720 | 0 | 387.720 | 128.284.916 | Neu | +100,0% | |
| DIMENSIONAL FUND ADVISORS LP | 384.205 | 0 | 384.205 | 127.071.024 | Neu | +100,0% | |
| FIRST TRUST ADVISORS LP | 382.701 | 0 | 382.701 | 126.624.127 | Neu | +100,0% | |
| Nuveen, LLC | 322.232 | 0 | 322.232 | 106.616.902 | Neu | +100,0% | |
| Sumitomo Mitsui Trust Group, Inc. | 314.417 | 0 | 314.417 | 104.031.153 | Neu | +100,0% | |
| CITIGROUP INC | 5.938.375 | 0 | 5.938.375 | 100.347.992 | Neu | +100,0% | |
| TD ASSET MANAGEMENT INC | 281.848 | 0 | 281.848 | 93.255.048 | Neu | +100,0% | |
| GILDER GAGNON HOWE & CO LLC | 280.092 | 0 | 280.092 | 92.674.097 | Neu | +100,0% | |
| Allspring Global Investments Holdings, LLC | 281.793 | 0 | 281.793 | 92.633.814 | Neu | +100,0% |
Top-Fondshalter (Stand: 30.06.2026) ⓘ
⚠ Vorläufige Daten: Erst 2951 von typischerweise 8401 Fonds (35 %) haben für dieses Quartal eingereicht. Vollständigkeit erwartet bis 14.08.2026. Auswertungen (NEW/INC/DEC) sind noch zu konservativ — viele Spätfiler erscheinen aktuell als „Exits".
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) | Stimmkontrolle | Verlauf |
|---|---|---|---|---|---|---|---|
| CONGRESS ASSET MANAGEMENT CO | 265.701 | 285.739 | -7,0% | 79.983.972 | 15,37 | 81 % | 4 Q |
| Robeco Institutional Asset Management B.V. | 188.084 | 126.463 | +48,7% | 56.618.929 | 10,88 | 63 % | 17 Q |
| Assenagon Asset Management S.A. | 155.695 | 128.896 | +20,8% | 46.868.866 | 9,01 | 100 % | 16 Q |
| Portman Square Capital LLP | 71.216 | 54.824 | +29,9% | 21.438.152 | 4,12 | 100 % | 15 Q |
| FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND | 66.985 | 48.705 | +37,5% | 20.164.494 | 3,88 | 100 % | 16 Q |
| Swedbank AB | 61.894 | 62.215 | -0,5% | 18.631.951 | 3,58 | 100 % | 16 Q |
| Mirae Asset Global Investments Co., Ltd. | 61.531 | 56.391 | +9,1% | 18.522.677 | 3,56 | 100 % | 17 Q |
| Asset Management One Co., Ltd. | 60.096 | 57.709 | +4,1% | 18.090.699 | 3,48 | 100 % | 17 Q |
| MACKAY SHIELDS LLC | 14.834.000 | 14.844.000 | -0,1% | 17.866.207 | 3,43 | 7 % | 12 Q |
| Mediolanum International Funds Ltd | 46.396 | 45.119 | +2,8% | 13.618.154 | 2,62 | 100 % | 8 Q |
| SIERRA SUMMIT ADVISORS LLC | 41.684 | 30.298 | +37,6% | 12.548.135 | 2,41 | 0 % | 2 Q |
| Resona Asset Management Co.,Ltd. | 40.053 | 39.832 | +0,6% | 12.006.717 | 2,31 | 100 % | 10 Q |
| Erste Asset Management GmbH | 36.719 | 36.310 | +1,1% | 10.777.761 | 2,07 | 17 % | 17 Q |
| FIDEURAM - INTESA SANPAOLO PRIVATE BANKING S.P.A. | 35.077 | 37.025 | -5,3% | 10.559.243 | 2,03 | 0 % | 3 Q |
| OFI INVEST ASSET MANAGEMENT | 37.945 | 729 | +5105,1% | 9.990.889 | 1,92 | 100 % | 8 Q |
| IFM Investors Pty Ltd | 29.661 | 27.266 | +8,8% | 8.928.851 | 1,72 | 100 % | 17 Q |
| Swiss Life Asset Management Ltd | 29.327 | 23.734 | +23,6% | 8.828.307 | 1,70 | 100 % | 16 Q |
| China Universal Asset Management Co., Ltd. | 25.269 | 27.266 | -7,3% | 7.606.727 | 1,46 | 100 % | 16 Q |
| Eurizon Capital SGR S.p.A. | 22.698 | 24.184 | -6,1% | 6.830.621 | 1,31 | 99 % | 3 Q |
| PensionDanmark Pensionsforsikringsaktieselskab | 22.451 | 34.570 | -35,1% | 6.758.425 | 1,30 | 0 % | 3 Q |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 30.06.2026 | vorl. | 202 | 24,0 | 510 |
| 31.03.2026 | ✓ | 799 | 495,4 | 43.513 |
| 31.12.2025 | ✓ | 848 | 729,2 | 52.990 |
| 30.09.2025 | ✓ | 833 | 529,2 | 60.503 |
| 30.06.2025 | ✓ | 672 | 1.169,2 | 41.665 |
| 31.03.2025 | ✓ | 645 | 1.274,8 | 34.265 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) |
|---|---|---|
| STEELHEAD PARTNERS LLC | 60.000.000 | 77.115.420 |
| CIBC Bancorp USA Inc. | 169.031 | 55.918.813 |
| DeepCurrents Investment Group LLC | 24.000.000 | 30.885.121 |
| Quadrature Capital Ltd | 85.241 | 28.203.690 |
| CSS LLC/IL | 18.563.000 | 23.857.743 |
| Jain Global LLC | 47.962 | 15.869.187 |
| M&G Plc | 37.656 | 12.464.136 |
| Aquatic Capital Management LLC | 31.061 | 10.277.153 |
| SIERRA SUMMIT ADVISORS LLC | 30.298 | 10.024.700 |
| SEB Asset Management AB | 30.153 | 9.976.723 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| BNP PARIBAS FINANCIAL MARKETS | 32.598.965 | 14.891.530 | +84.1 % | 134.378.407 |
| BANK OF AMERICA CORP /DE/ | 11.872.912 | 11.182.735 | +1620.3 % | 333.898.281 |
| TWO SIGMA INVESTMENTS, LP | 7.992.577 | 7.376.457 | +1197.2 % | 666.972.952 |
| CITIGROUP INC | 5.920.375 | 5.128.813 | +647.9 % | 94.392.332 |
| BNP Paribas Asset Management Holding S.A. | 9.930.012 | 5.070.408 | +104.3 % | 72.117.432 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | 8.354.708 | 3.685.063 | +78.9 % | 56.667.663 |
| BlackRock, Inc. | 27.044.908 | 3.594.034 | +15.3 % | 3.477.179.610 |
| T. Rowe Price Investment Management, Inc. | 5.193.324 | 3.439.684 | +196.1 % | 1.718.316 |
| MORGAN STANLEY | 4.122.681 | 3.032.524 | +278.2 % | 335.756.376 |
| Capital Research Global Investors | 9.471.181 | 2.691.473 | +39.7 % | 3.133.497.254 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| VOYA INVESTMENT MANAGEMENT LLC | 148.488 | -139.840.125 | -99.9 % | 49.130.225 |
| LORD, ABBETT & CO. LLC | 1.204.000 | -6.568.406 | -84.5 % | 1.546 |
| Capital World Investors | 10.802.348 | -5.499.424 | -33.7 % | 3.573.758.048 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 14.462.365 | -4.401.047 | -23.3 % | 236.917.314 |
| STATE OF WISCONSIN INVESTMENT BOARD | 68.883 | -2.997.182 | -97.8 % | 22.791.318 |
| FMR LLC | 33.023.166 | -2.372.983 | -6.7 % | 4.847.444.679 |
| GOLDMAN SACHS GROUP INC | 843.388 | -950.935 | -53.0 % | 155.785.748 |
| WELLS FARGO & COMPANY/MN | 1.252.763 | -432.877 | -25.7 % | 114.580.889 |
| UBS Group AG | 481.540 | -344.970 | -41.7 % | 151.855.369 |
| KBC Group NV | 20.524 | -327.670 | -94.1 % | 6.791 |
Zusätzlich aktuell von 305 Mutual Funds/ETFs gehalten (N-PORT). Alle Fondsgesellschaften & ihre 4-Quartals-Bewegungen →
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Δ-Balken |
|---|---|---|---|---|---|---|
| 14.05.2026 | Capital World Investors | Passiv (13G/A) | 8,20 % | 10.916.799 | -4,90 pp | |
| 14.05.2026 | Capital Research Global Investors | Passiv (13G/A) | 7,10 % | 9.471.181 | +1,70 pp | |
| 06.05.2026 | Abigail P. Johnson (+1) | Passiv (13G/A) | 11,00 % | 14.640.525 | -1,80 pp | |
| 29.04.2026 | Vanguard Capital Management | Passiv (13G) | 5,35 % | 7.104.536 | Neu | |
| 26.03.2026 | The Vanguard Group | Passiv (13G/A) | Ausstieg | 0 | -10,03 pp | |
| 05.11.2025 | Abigail P. Johnson (+1) | Passiv (13G/A) | 12,80 % | 16.834.095 | Neu | |
| 07.04.2025 | The Vanguard Group | Passiv (13G/A) | 10,03 % | 13.056.605 | +0,51 pp | |
| 13.02.2025 | Capital Research Global Investors | Passiv (13G) | 5,40 % | 6.968.513 | Neu | |
| 08.11.2024 | Wellington Investment Advisors Holdings LLP (+2) | Passiv (13G/A) | 3,91 % | 5.018.779 | -1,87 pp | |
| 05.07.2024 | Baillie Gifford & Co (Scottish partnership) | Passiv (13G/A) | 4,77 % | 6.032.656 | -0,78 pp | |
| 13.02.2024 | The Vanguard Group | Passiv (13G/A) | 9,52 % | 11.943.895 | +0,17 pp | |
| 09.02.2024 | Capital World Investors | Passiv (13G/A) | 13,10 % | 16.398.889 | -0,40 pp | |
| 09.02.2024 | Wellington Management Company LLP | Passiv (13G/A) | 5,62 % | 7.055.912 | +0,13 pp | |
| 09.02.2024 | Wellington Investment Advisors Holdings LLP (+2) | Passiv (13G/A) | 5,78 % | 7.252.907 | +0,69 pp | |
| 29.01.2024 | Baillie Gifford & Co (Scottish partnership) | Passiv (13G/A) | 5,55 % | 6.967.097 | -2,10 pp | |
| 26.01.2024 | . BlackRock, Inc. | Passiv (13G/A) | 6,80 % | 8.546.557 | -0,20 pp | |
| 14.02.2023 | T. ROWE PRICE ASSOCIATES, INC. | Passiv (13G/A) | 3,30 % | 4.074.144 | -2,10 pp | |
| 13.02.2023 | Capital World Investors | Passiv (13G/A) | 13,50 % | 16.593.958 | +2,80 pp | |
| 09.02.2023 | The Vanguard Group | Passiv (13G/A) | 9,35 % | 11.507.116 | +0,40 pp | |
| 06.02.2023 | Wellington Investment Advisors Holdings LLP (+2) | Passiv (13G/A) | 5,09 % | 6.261.642 | -0,63 pp | |
| 31.01.2023 | . BlackRock, Inc. | Passiv (13G/A) | 7,00 % | 8.665.702 | +0,60 pp | |
| 19.01.2023 | Baillie Gifford & Co (Scottish partnership) | Passiv (13G/A) | 7,65 % | 9.407.871 | -1,23 pp | |
| 09.09.2022 | Capital World Investors | Passiv (13G) | 10,70 % | 12.816.777 | Neu | |
| 14.02.2022 | T. ROWE PRICE ASSOCIATES, INC. | Passiv (13G) | 5,40 % | 6.535.368 | Neu | |
| 09.02.2022 | The Vanguard Group | Passiv (13G/A) | 8,95 % | 10.702.771 | -0,11 pp | |
| 04.02.2022 | Wellington Investment Advisors Holdings LLP (+2) | Passiv (13G/A) | 5,72 % | 6.839.821 | -2,94 pp | |
| 04.02.2022 | Wellington Management Company LLP | Passiv (13G/A) | 5,49 % | 6.564.021 | -2,82 pp | |
| 03.02.2022 | . BlackRock, Inc. | Passiv (13G/A) | 6,40 % | 7.671.402 | -1,10 pp | |
| 18.01.2022 | Baillie Gifford & Co (Scottish partnership) | Passiv (13G/A) | 8,88 % | 10.616.751 | +1,02 pp |
US Congress Trades (STOCK Act)
| Datum | Mitglied | Partei | Kammer | Typ | Betrag-Bereich |
|---|---|---|---|---|---|
| 12.05.2025 | Jefferson Shreve | – | House | Verkauf | $15,001 – $50,000 |
Quelle: House eFD & Senate eFD (STOCK Act PTR). Betragsangaben sind Bereichsangaben — keine Exaktwerte. Tiefenanalyse für diese Aktie → · Alle Kongress-Bestände →
Finanzkennzahlen (SEC XBRL) ⓘ
Währung:
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | – | 313.747.000 $ | 2,33 $ | 4.966.331.000 $ | 789.176.000 $ |
| 2025-09-30 | 10-Q | – | 251.084.000 $ | 1,84 $ | 4.851.662.000 $ | 233.894.000 $ |
| 2025-06-30 | 10-Q | – | -66.277.000 $ | -0,51 $ | 4.566.019.000 $ | 250.591.000 $ |
| 2025-03-31 | 10-K | – | – | – | – | – |
| 2025-03-31 | 10-Q | – | -57.479.000 $ | -0,44 $ | 4.213.811.000 $ | 115.435.000 $ |
| 2024-12-31 | 10-K | – | -278.157.000 $ | -2,18 $ | 4.239.983.000 $ | 67.088.000 $ |
| 2024-09-30 | 10-Q | – | -111.570.000 $ | -0,87 $ | 4.205.039.000 $ | 32.354.000 $ |
| 2024-06-30 | 10-Q | – | -16.889.000 $ | -0,13 $ | 4.009.634.000 $ | -3.067.000 $ |
| 2024-03-31 | 10-Q | – | -65.935.000 $ | -0,52 $ | 3.824.386.000 $ | -219.272.000 $ |
| 2023-12-31 | 10-K | – | -440.242.000 $ | -3,52 $ | 3.829.880.000 $ | -220.644.000 $ |
| 2023-09-30 | 10-Q | – | 147.753.000 $ | 1,15 $ | 3.839.073.000 $ | -165.866.000 $ |
| 2023-06-30 | 10-Q | – | -276.024.000 $ | -2,21 $ | 3.402.396.000 $ | -408.131.000 $ |
| 2023-03-31 | 10-Q | – | -174.101.000 $ | -1,40 $ | 3.391.940.000 $ | -259.240.000 $ |
| 2022-12-31 | 10-K | 1.037.418.000 $ | -1.131.156.000 $ | -9,30 $ | 3.546.359.000 $ | -158.223.000 $ |
| 2022-09-30 | 10-Q | 264.306.000 $ | -405.920.000 $ | -3,32 $ | 3.535.255.000 $ | -67.638.000 $ |
| 2022-06-30 | 10-Q | 224.818.000 $ | -277.402.000 $ | -2,29 $ | 3.330.417.000 $ | 176.040.000 $ |
| 2022-03-31 | 10-Q | 213.259.000 $ | -240.341.000 $ | -2,00 $ | 3.433.545.000 $ | 401.166.000 $ |
| 2021-12-31 | 10-K | 844.287.000 $ | -852.824.000 $ | -7,20 $ | 3.643.304.000 $ | 588.203.000 $ |
| 2021-09-30 | 10-Q | 187.633.000 $ | -204.514.000 $ | -1,72 $ | 3.472.313.000 $ | 755.893.000 $ |
| 2021-06-30 | 10-Q | 220.553.000 $ | -189.559.000 $ | -1,61 $ | 3.509.429.000 $ | 853.362.000 $ |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| Product | 3,0 Mrd. | 1,6 Mrd. | 1,2 Mrd. | 894,3 Mio. | 662,1 Mio. | 80,4 % | +81,4% | |
| TTR | 2,5 Mrd. | – | – | – | – | 67,0 % | Neu | |
| Amvuttra | 2,3 Mrd. | 970,5 Mio. | 557,8 Mio. | 93,8 Mio. | – | 62,3 % | +138,4% | |
| Collaborations | 553,4 Mio. | 510,2 Mio. | 546,2 Mio. | – | – | 14,9 % | +8,5% | |
| Rare | 499,9 Mio. | – | – | – | – | 13,5 % | Neu | |
| GIVLAARI | 308,5 Mio. | 255,9 Mio. | 219,3 Mio. | 173,1 Mio. | 127,8 Mio. | 8,3 % | +20,6% | |
| OXLUMO | 191,4 Mio. | 167,1 Mio. | 109,8 Mio. | 69,8 Mio. | 59,6 Mio. | 5,2 % | +14,6% | |
| Royalty | 174,0 Mio. | 91,8 Mio. | 40,6 Mio. | 8,2 Mio. | 1,2 Mio. | 4,7 % | +89,6% | |
| ONPATTRO | 172,8 Mio. | 252,9 Mio. | 354,5 Mio. | 557,6 Mio. | 474,7 Mio. | 4,7 % | -31,7% |
Quartalsverlauf
| Segment | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q3 FY2024 | Q2 FY2024 | Q1 FY2024 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Product | 851,1 Mio. | 672,2 Mio. | 468,5 Mio. | 420,1 Mio. | 410,1 Mio. | 365,2 Mio. | 68,1 % | +102,6% | |
| TTR | 724,4 Mio. | 544,5 Mio. | 359,5 Mio. | – | – | – | 58,0 % | Neu | |
| Amvuttra | 685,3 Mio. | 492,0 Mio. | 310,0 Mio. | 258,6 Mio. | 230,1 Mio. | 195,2 Mio. | 54,9 % | +165,0% | |
| Collaborations | 351,7 Mio. | 61,5 Mio. | 99,2 Mio. | 57,4 Mio. | 227,3 Mio. | 118,5 Mio. | 28,2 % | +512,9% | |
| Rare | 126,7 Mio. | 127,7 Mio. | 109,1 Mio. | – | – | – | 10,1 % | Neu | |
| GIVLAARI | 73,9 Mio. | 80,8 Mio. | 67,0 Mio. | 71,0 Mio. | 62,1 Mio. | 58,1 Mio. | 5,9 % | +4,0% | |
| OXLUMO | 52,8 Mio. | 46,9 Mio. | 42,1 Mio. | 40,2 Mio. | 40,6 Mio. | 42,6 Mio. | 4,2 % | +31,4% | |
| Royalty | 46,2 Mio. | 40,0 Mio. | 26,5 Mio. | 23,4 Mio. | 22,4 Mio. | 10,6 Mio. | 3,7 % | +97,6% | |
| ONPATTRO | 39,1 Mio. | 52,5 Mio. | 49,5 Mio. | 50,3 Mio. | 77,2 Mio. | 69,2 Mio. | 3,1 % | -22,3% |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q3 2025 | 30.09.2025 | 30.10.2025 | 1,2 Mrd. USD | 1,84 |
| Q2 2025 | 30.06.2025 | 31.07.2025 | 773,7 Mio. USD | -0,51 |
| Q1 2025 | 31.03.2025 | 01.05.2025 | 594,2 Mio. USD | -0,44 |
| Q3 2024 | 30.09.2024 | 31.10.2024 | 500,9 Mio. USD | -0,87 |
| Q2 2024 | 30.06.2024 | 01.08.2024 | 659,8 Mio. USD | -0,13 |
| Q1 2024 | 31.03.2024 | 02.05.2024 | 494,3 Mio. USD | -0,52 |
| Q3 2023 | 30.09.2023 | 02.11.2023 | 750,5 Mio. USD | 1,15 |
| Q2 2023 | 30.06.2023 | 03.08.2023 | 318,8 Mio. USD | -2,21 |
| Q1 2023 | 31.03.2023 | 04.05.2023 | 319,3 Mio. USD | -1,40 |
Einreichungs-Historie (10-K / 10-Q / 20-F / 6-K)
SEC-Einreichungs-Historie der letzten sechs Jahre (Datum = US-Kalendertag,
SEC/ET): Quartalsberichte (10-Q) und Jahresberichte (10-K); ausländische
Emittenten (ADR/Foreign Private Issuer) reichen stattdessen Jahresberichte
(20-F/40-F) und Zwischenmitteilungen (6-K) ein — dort liegt im SEC-Index
keine Berichtsperiode vor, Periode und Verzögerung bleiben leer. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht (US) | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 30.04.2026 | 10-Q | 31.03.2026 | 30 Tage | SEC » |
| 12.02.2026 | 10-K | 31.12.2025 | 43 Tage | SEC » |
| 30.10.2025 | 10-Q | 30.09.2025 | 30 Tage | SEC » |
| 31.07.2025 | 10-Q | 30.06.2025 | 31 Tage | SEC » |
| 01.05.2025 | 10-Q | 31.03.2025 | 31 Tage | SEC » |
| 13.02.2025 | 10-K | 31.12.2024 | 44 Tage | SEC » |
| 31.10.2024 | 10-Q | 30.09.2024 | 31 Tage | SEC » |
| 01.08.2024 | 10-Q | 30.06.2024 | 32 Tage | SEC » |
| 02.05.2024 | 10-Q | 31.03.2024 | 32 Tage | SEC » |
| 15.02.2024 | 10-K | 31.12.2023 | 46 Tage | SEC » |
| 02.11.2023 | 10-Q | 30.09.2023 | 33 Tage | SEC » |
| 03.08.2023 | 10-Q | 30.06.2023 | 34 Tage | SEC » |
| 04.05.2023 | 10-Q | 31.03.2023 | 34 Tage | SEC » |
| 23.02.2023 | 10-K | 31.12.2022 | 54 Tage | SEC » |
| 27.10.2022 | 10-Q | 30.09.2022 | 27 Tage | SEC » |
| 28.07.2022 | 10-Q | 30.06.2022 | 28 Tage | SEC » |
| 28.04.2022 | 10-Q | 31.03.2022 | 28 Tage | SEC » |
| 10.02.2022 | 10-K | 31.12.2021 | 41 Tage | SEC » |
| 28.10.2021 | 10-Q | 30.09.2021 | 28 Tage | SEC » |
| 03.08.2021 | 10-Q | 30.06.2021 | 34 Tage | SEC » |
| 29.04.2021 | 10-Q | 31.03.2021 | 29 Tage | SEC » |
| 11.02.2021 | 10-K | 31.12.2020 | 42 Tage | SEC » |
| 05.11.2020 | 10-Q | 30.09.2020 | 36 Tage | SEC » |
| 06.08.2020 | 10-Q | 30.06.2020 | 37 Tage | SEC » |
Proxy-/Governance-Filings
Proxy-Statements (SEC DEF-14A-Familie) der letzten sechs Jahre: reguläre HV-Einladungen zur Aktionärsversammlung, Aktivisten-Proxy-Fights (contested / Non-Management-Solicitation) und M&A-Abstimmungen.
| Datum (US) | Kategorie | HV-Termin (US) | Stichtag (US) | Form | |
|---|---|---|---|---|---|
| 06.04.2026 | HV-Einladung | — | — | DEFA14A | SEC » |
| 06.04.2026 | HV-Einladung | 20.05.2026 Jahres-HV | 25.03.2026 | DEF 14A | SEC » |
| 04.04.2025 | HV-Einladung | — | — | DEFA14A | SEC » |
| 24.03.2025 | HV-Einladung | — | — | DEFA14A | SEC » |
| 24.03.2025 | HV-Einladung | 08.05.2025 Jahres-HV | 10.03.2025 | DEF 14A | SEC » |
| 14.03.2025 | Vorläufig | — | — | PRE 14A | SEC » |
| 01.04.2024 | HV-Einladung | — | — | DEFA14A | SEC » |
| 01.04.2024 | HV-Einladung | 16.05.2024 Jahres-HV | 22.03.2024 | DEF 14A | SEC » |
| 03.04.2023 | HV-Einladung | — | — | DEFA14A | SEC » |
| 03.04.2023 | HV-Einladung | 18.05.2023 Jahres-HV | 24.03.2023 | DEF 14A | SEC » |
| 05.04.2022 | HV-Einladung | — | — | DEFA14A | SEC » |
| 05.04.2022 | HV-Einladung | 18.05.2022 Jahres-HV | 28.03.2022 | DEF 14A | SEC » |
| 02.04.2021 | HV-Einladung | — | — | DEFA14A | SEC » |
| 02.04.2021 | HV-Einladung | 18.05.2021 Jahres-HV | 29.03.2021 | DEF 14A | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). HV-Termin = Datum der Aktionärsversammlung, Stichtag (Record Date) = Nachweisstichtag für die Stimmberechtigung (aus dem Dokument extrahiert).
Filing-Analyse (10-K / 10-Q)
Narrative-Analyse der letzten Quartals-/Jahresberichte durch Claude (nur Coverage-Gruppen-Mitglieder). Keine Anlageberatung — der qualitative Score dient der Einordnung, nicht als Kaufempfehlung; siehe allgemeiner Hinweis am Seitenende.
🔒 Die aufklappbare Detailanalyse (Red Flags, Risiko-Änderungen, Guidance-Zitate, voller Wortlaut) ist Teil des Kunden-Abos — freischalten.
| Datum | Form | Stimmung | Guidance | Risiko-Δ | Qualitativ | Zusammenfassung | |
|---|---|---|---|---|---|---|---|
| 12.02.2026 | 10-K | 0,42 | ↑ | 0,00 | 68 | Alnylam erzielte 2025 erstmals in der Unternehmensgeschichte einen Jahresüberschuss von $313,7 Mio. bei einem Gesamtumsatz von $3,71 Mrd. (+65% ggü. Vorjahr), getrieben durch das explosive Wachstum von AMVUTTRA im US-Markt für ATTR-CM (+175% in den … | 🔒 |
Kritische 8-K Meldungen ⓘ
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (27.05.2026)
HOCH Abgang Schlüsselpersonen (27.05.2026)
| Datum | Meldung | Tags | Schwere | Filing | Auszug |
|---|---|---|---|---|---|
| 27.05.2026 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers… |
| 04.03.2026 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | n 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors… |
| 03.12.2025 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers… |
| 18.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 05.03.2025 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | n 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Principal Officers; Election of Directors… |
| 06.08.2020 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
8-K-Ereignisse (KI)
🔒 Die vollständige KI-Einordnung je 8-K ist Teil des Kunden-Abos — freischalten.
| Datum | Ereignis | Sentiment | Materialität | Zusammenfassung | Filing |
|---|---|---|---|---|---|
| 27.05.2026 | Personalwechsel | 0,10 | 30 | Verwaltungsrat von 10 auf 11 Mitglieder erweitert; Benjamin F. Cravatt, Ph.D. ab 1. Juni 2026 als Direktor gewählt. | SEC |
| 30.04.2026 | Quartalszahlen | 0,00 | 45 | Alnylam gab am 30. April 2026 die Finanzzielergebnisse für das Q1 2026 (bis 31. März) bekannt. | SEC |
| 04.03.2026 | Personalwechsel | 0,00 | 70 | Alnylam vergibt spezielle Aktienauszeichnung an Vorstandsmitglied effektiv 2. März 2026 nach Empfehlung des Vergütungsausschusses. | SEC |
| 12.02.2026 | Quartalszahlen | 0,00 | 45 | Alnylam Pharmaceuticals meldete die Finanzergebnisse für das vierte Quartal 2025 (zum 31. Dezember 2025). Die vollständige Pressemitteilung … 🔒 | SEC |
| 12.01.2026 | Quartalszahlen | 0,40 | 72 | Alnylam kündigte die Fünf-Jahres-Strategie "Alnylam 2030" an und meldete vorläufige FY-2025-Umsätze von 2,987 Mrd. USD für Kernprodukte sowi… 🔒 | SEC |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-06-22 | 6 | 278,09 | 1.669 |
| 2026-06-18 | 4 | 282,72 | 1.131 |
| 2026-06-12 | 22.234 | 289,39 | 6.434.297 |
| 2026-06-09 | 75 | 292,16 | 21.912 |
| 2026-06-08 | 6.664 | 303,05 | 2.019.525 |
| 2026-06-05 | 6.912 | 303,64 | 2.098.760 |
| 2026-05-12 | 18.560 | 284,84 | 5.286.630 |
| 2026-05-11 | 1 | 295,05 | 295 |
| 2026-05-07 | 14 | 303,00 | 4.242 |
| 2026-04-24 | 15 | 313,79 | 4.707 |
| 2026-04-14 | 3 | 333,00 | 999 |
| 2026-04-10 | 598 | 321,28 | 192.125 |
| 2026-04-08 | 489 | 319,52 | 156.245 |
| 2026-04-07 | 486 | 330,34 | 160.545 |
| 2026-04-06 | 47 | 318,85 | 14.986 |
| 2026-03-31 | 450 | 316,09 | 142.241 |
| 2026-03-23 | 4.372 | 312,17 | 1.364.807 |
| 2026-03-19 | 3 | 314,80 | 944 |
| 2026-03-16 | 583 | 313,41 | 182.718 |
| 2026-03-03 | 14.083 | 325,07 | 4.577.961 |
| 2026-03-02 | 2.101 | 332,92 | 699.465 |
| 2026-02-12 | 1 | 322,28 | 322 |
| 2026-02-09 | 2 | 328,16 | 656 |
| 2026-02-02 | 30 | 338,06 | 10.142 |